Table 2.

Estrone, estradiol, and SHBG concentrations (geometric means, 95% CI) at baseline and 6-month follow-up

Aspirin (N = 76)Placebo (N = 68)
Baseline (95% CI)Follow-up (95% CI)ΔA (%)Baseline (95% CI)Follow-up (95% CI)ΔP (%)Pa
Estrone, pg/mL31.1 (29.0–33.3)31.5 (29.4–33.9)0.4 (1.3)33.4 (30.8–36.2)33.3 (30.8–36.1)−0.1 (−0.3)0.75
Estradiol, pg/mL7.25 (6.49–8.09)7.42 (6.72–8.20)0.17 (2.3)7.58 (6.84–8.40)7.72 (6.92–8.62)0.14 (1.8)0.94
Free estradiol, pg/mL0.177 (0.156–0.200)0.180 (0.161–0.202)0.003 (1.7)0.180 (0.159–0.203)0.182 (0.160–0.207)0.002 (1.1)0.96
Bioavailable estradiol, pg/mL4.53 (4.01–5.11)4.58 (4.08–5.13)0.05 (1.1)4.56 (404–5.15)4.62 (4.08–5.24)−0.06 (−1.3)0.97
SHBG, nmol/L45.9 (41.5–50.7)47.3 (42.7–52.4)1.4 (3.1)51.1 (46.3–56.4)51.7 (46.9–57.0)0.6 (1.2)0.46
  • ΔP, change in the control (placebo) group at 6 months from baseline; ΔA, change in the aspirin group at 6 months from baseline.

  • aP value, GEE model, comparing the change at 6-month follow-up from baseline between the placebo and aspirin groups.